




TARGACELL

A non-invasive stem cell delivery system
using proprietary proteins to repair damaged hearts



COMPANY OVERVIEW



TargaCell Corporation is a Chicago-based biotech firm dedicated to repairing damaged hearts, improving their function and restoring the quality of life for people with heart disease. TargaCell's technology delivers 10 X more adult stem cells, intravenously, to the damaged heart, without heart catheterization, to enhance repair & restore heart function, more efficiently than current heart repair clinical regenerative medicine protocols.

WHAT IS TARGACELL ?



TargaCell is a stem cell delivery company that can deliver 10X more stem cells to the heart and have them retained to dramatically improve the repair of damaged heart tissue resulting from a heart attack.

WHAT WE DO




Universal Delivery Technology

TargaCell can provide delivery of all major types of stem cells used in heart repair



Safe & Efficient

We provide a safe, efficient intravenous, stem cell delivery, without anesthesia or cardiac catheter



Delivery & Retainment

We deliver and retain these stem cells in the heart to expedite repair of damage and restore function to improve quality of life

SENDING STEM CELLS TO THE HEART

PROBLEM - Current Method

- Invasive
- Risky
- Catheterization Under Anesthesia
- Expensive ~ \$100K
- Too few stem cells delivered & retained!
- Inefficient repair
- Can't be repeated often

OUR SOLUTION

- Easy, low risk
- No catheter
- Good delivery & retention of stem cells
- Maximizes repair
- No cell trapping in risky places
- Universal delivery for stem cells
- Can be repeated often
- Less cost \$20-40K
- Stem Cells

MEET THE TEAM



Catherine A. Phillips, PhD
CEO/CSO



Robin McWherter
Chief, Research Operations
& Facilities



Mark F Pittenger, PhD
World Class Stem Cell Expert



Matthew Raymond PhD, MBA
VP Business Development



Patrick D. Lamb, JD
General Counsel



David Ellison, CPA
CFO



Susan BallKell, DVM, PhD Director
Pathology & Toxicology

TESTIMONIALS

TargaCell's Solutions to Current Methods & Problems

“

The [TargaCell] non-invasive delivery procedure would make it much easier to enroll patients

Regarding current methods, "... where [do] these cells go once they are injected into the wall because clearly most of them don't remain there for very long

Gary Schaer, MD, Professor Cardiology & Director of Translational Medicine Research, Rush University, Chicago, IL

”

“


Catheter delivery will not be the future of stem cell delivery for heart regeneration...too few cells can be delivered and retained to have this therapy reach its potential."

...your [TargaCell's] technology has the potential to do this...


Douglas Losordo, MD, Chief Medical Officer, Caladrius; (while Prof. Cardiology Northwestern University Feinberg School of Medicine)

”

TARGACELL BUSINESS MODEL



TECHNOLOGY DEVELOPMENT PLAN




\$0.8-2.0MM OVER THE NEXT 2 YEARS

HEART REPAIR CHALLENGE

The cost of heart disease SOARS!

>40% of US adults will have CVD by **2030**



Cardiovascular Regenerative Medicine
44% of the market (CAGR 30-37%)

\$2.9-\$6.5B

2016

\$11.0B

2020

\$500 Million+ Targacell's projected market opportunity for heart repair

INVESTMENT TERMS



CONTACT US

Catherine A. Phillips, PhD, CEO/CSO

Email: littledoccap0@gmail.com

Cell: 806.433.0795

Robin McWherter, CMRT, President/Chief, Research

Operations & Facilities

Email: rmcwherter3@gmail.com

Cell: 806.433.0796